FRM
KRYS icon

Fox Run Management’s Krystal Biotech KRYS Stock Holding History

Fox Run Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-856
Closed -$211K – 1073
2025
Q4 		$211K Buy
+856
New +$180K 0.03% 790
2025
Q2 		– Sell
-2,354
Closed -$424K – 1053
2025
Q1 		$424K Buy
2,354
+193
+9% +$32.5K 0.07% 555
2024
Q4 		$339K Buy
+2,161
New +$383K 0.06% 587
2024
Q1 		– Sell
-3,436
Closed -$426K – 938
2023
Q4 		$426K Buy
3,436
+1,544
+82% +$171K 0.11% 364
2023
Q3 		$219K Buy
+1,892
New +$231K 0.07% 537

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's KRYS Position: Q1 2026 in Review

Fox Run Management sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 856 shares — an estimated $211K sold.

Fox Run Management first reported a position in KRYS in Q3 2023 and held it in 5 quarters. The position peaked at $426K in Q4 2023. 368 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Fox Run Management reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 856 Krystal Biotech shares in Q1 2026, an estimated $211K.
  • Fox Run Management first reported a position in Krystal Biotech in Q3 2023 and held it in 5 quarters.
  • Fox Run Management's Krystal Biotech position peaked at $426K in Q4 2023.
  • 368 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.